SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Milton Packer(Baylor University Medical Center), Martina Brueckmann, Javed Butler(Jackson Memorial Hospital), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Anne Pernille Ofstad(Boehringer Ingelheim (Norway)), Egon Pfarr(Boehringer Ingelheim (Germany)), Stefan D. Anker(Bayer (Germany)), João Pedro Ferreira(Inserm), Waheed Jamal(Inserm)
Cited by 1,373
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k